SWX:SDZPharmaceuticals
Did Sandoz’s Expanded Henlius Biosimilar Pact Just Redraw Its (SWX:SDZ) Investment Narrative?
Sandoz Group AG recently announced a collaboration agreement with Shanghai Henlius Biotech, Inc. to develop, manufacture and commercialise up to 10 biosimilars, including proposed versions of cetuximab, evolocumab and belimumab, with Henlius handling development and manufacturing and Sandoz holding commercial rights outside China under a milestones-based deal of up to US$322 million.
This partnership lifts Sandoz’s biosimilar pipeline from 39 assets with potential to reach up to 46,...